---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-22-000035"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2022-04-25T23:59:59+00:00"
generated_at: "2026-06-26T05:05:20.904635+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Phase 2 SHIFT-UC trial of GB004 misses primary endpoint; study terminated

## Summary
- Phase 2 trial of GB004 in mild-to-moderate active UC failed primary endpoint at week 12 (15.4% QD, 22.5% BID vs. placebo 17.9%).
- No meaningful differences on secondary endpoints; Gossamer terminates treat-through and open-label extension portions.
- Preliminary cash, cash equivalents, and marketable securities ~$272M as of March 31, 2022 (unaudited).
- Target enrollment of 80 patients reached in Phase 2 TORREY trial of seralutinib in PAH; topline results expected Q4 2022.
- Anticipates initiation of Phase 1b/2 STAR CNS trial of GB5121 in primary CNS lymphoma in late Q2 2022.

## SEC filing metadata
- accession: 0001728117-22-000035
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2022-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000035/0001728117-22-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000035/goss-20210425x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-22-000035
- JSON: https://secwatch.observer/filing/0001728117-22-000035.json
- Plain text: https://secwatch.observer/filing/0001728117-22-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.